Sovel 400 mg+100 mg (Tablet)
Unit Price: ৳ 1,000.00 (1 x 7: ৳ 7,000.00)
Strip Price: ৳ 7,000.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Sofosbuvir velpatasvir |
| Company | Aci limited |
Indications
- Indicated for the treatment of adult and pediatric patients with chronic HCV genotypes 1, 2, 3, 4, 5, or 6 infection
- Indicated for use in patients without cirrhosis or with compensated cirrhosis
- Indicated for use in patients with decompensated cirrhosis in combination with ribavirin
Mechanism of Action
- Sofosbuvir is an inhibitor of HCV NS5B RNA-dependent RNA polymerase
- Velpatasvir is an inhibitor of HCV NS5A protein
- GS-461203 acts as a chain terminator in HCV RNA replication
Dosage & Administration
- Dosage based on patient population and HCV genotype
- Recommended dosage for adults: one tablet (400 mg sofosbuvir and 100 mg velpatasvir) once daily with or without food
- Recommended dosage for pediatric patients: based on weight and HCV genotype
Potential Drug Interactions
- Sofosbuvir & Velpatasvir are substrates of drug transporters P-gp and BCRP
- In vitro, slow metabolic turnover of Velpatasvir by CYP2B6, CYP2C8, and CYP3A4 was observed
- Substances that induce P-gp and/or CYP enzymes may decrease plasma concentrations of Sofosbuvir & Velpatasvir
Contraindications
- Contraindicated in patients for whom ribavirin is contraindicated
Side Effects
- Common side effects include fatigue, nausea, headache, anemia, diarrhea, insomnia, pruritus, muscle spasm, dyspnea, and cough
- Rare adverse events include reduced hemoglobin, lymphocyte count, neutrophil count, and platelet count
Pregnancy & Lactation
- Contraindicated in pregnant women and in men whose female partners are pregnant when administered with ribavirin
- Unknown impact on human breast milk production and breastfed infants
Precautions & Warnings
- Risk of Hepatitis B Virus Reactivation in Patients Coinfected with HCV and HBV
- Risk of serious symptomatic bradycardia when coadministered with amiodarone
- Warnings and precautions associated with ribavirin apply to Sofosbuvir & Velpatasvir combination treatment
Use in Special Populations
- Age does not have a clinically relevant effect on exposure to Sofosbuvir & Velpatasvir
- Pharmacokinetics of Sofosbuvir & Velpatasvir studied in patients with renal or hepatic impairments
Overdose Effects
- No specific antidote available for overdose
- Monitoring of vital signs and patient's clinical status recommended
- Hemodialysis may efficiently remove the predominant circulating metabolite of Sofosbuvir
Therapeutic Class
- Hepatic viral infections (Hepatitis C)
Storage Conditions
- Store in a cool and dry place, preferably below 30°C
- Keep out of reach of children